Théa completes eyecare expansion with Akorn's branded ophthalmic products

,

The purchase gives Théa ownership over seven products across the therapeutic space, including glaucoma and ocular surface disease.


Théa Pharma Inc has finished its acquisition of seven branded ophthalmic products from Akorn Operating Company LLC., the company announced Wednesday.

With this latest development, Théa now owns the following products:

  • Zioptan(tafluprost ophthalmic solution), a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • AcellFX (acellular amniotic membrane), which provides a protective environment or covering for repair to the ocular surface.
  • Betimol(timolol ophthalmic solution), indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
  • Cosopt (dorzolamide HCl and timolol maleate ophthalmic solution), indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to beta blockers.
  • Cosopt PF (dorzolamide HCl and timolol maleate ophthalmic solution), indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to beta blockers.
  • AzaSite (azithromycin ophthalmic solution), a macrolide antibiotic indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of certain microorganisms; and

Akten (lidocaine HCl ophthalmic gel), a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures.

Also included in the purchase is Akorn's nearly 50-person sales force, which Théa intends to expand with the anticipated launch and growth of additional products within the US.

“The closing of this transaction bolsters Théa’s mission to provide innovative treatments across a range of therapeutic areas, including glaucoma, dry eye, allergy, and inflammation,” said Théa President Jean-Frédéeric Chibret, in a statement.

Théa’s acquisition is part of the company’s larger commitment to develop cutting-edge products for the U.S. market in areas of unmet needs, according to the release.

Launch activities have also begun this month for its evidence-based line of iVIZIA OTC products for eyelid hygiene and dry eye, the company stated. Further, last month Théa its filed its first New Drug Application (NDA) from the FDA for a version of latanoprost.

Related: Théa to acquire 7 branded ophthalmic products from Akorn